Sorry to have given you the wrong impression Harry but at the bottom of the table I clumsily attempted to insert, I noted that the Agreement didn't include MSB'S diabetic kidney disease and rheumatoid arthritis products. However, results from both these Phase II are expected during the Agreement period and given that Celgene has an existing franchise in these areas, I am merely pointing out the potential for Celgene to look at licensing these as well.
Sorry to have given you the wrong impression Harry but at the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.015(1.29%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $4.551M | 3.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 98246 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 19079 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |